2024
Perceptions of cancer prevention options for Lynch syndrome (LS) in a multi-national convenience sample.
Hall M, Singhal S, Osorio N, Chavez J, Riggs E, Chertock Y, Daly M. Perceptions of cancer prevention options for Lynch syndrome (LS) in a multi-national convenience sample. Journal Of Clinical Oncology 2024, 42: 77-77. DOI: 10.1200/jco.2024.42.3_suppl.77.Peer-Reviewed Original ResearchLynch syndromeCancer prevention optionsCA riskNon-usersOne-time surveySupport groupsConvenience sampleCA preventionStratified analysisFox Chase Cancer CenterNegative public attitudesPrevention optionsColonoscopyMSI-H tumorsCA-PTPerceptions of efficacyCancer CenterSide-effect riskPersonal historyBelief statementsSide effect concernsInternational patientsSide effectsMSI-HRisk
2022
Refining colorectal cancer classification and clinical stratification through a single-cell atlas
Khaliq A, Erdogan C, Kurt Z, Turgut S, Grunvald M, Rand T, Khare S, Borgia J, Hayden D, Pappas S, Govekar H, Kam A, Reiser J, Turaga K, Radovich M, Zang Y, Qiu Y, Liu Y, Fishel M, Turk A, Gupta V, Al-Sabti R, Subramanian J, Kuzel T, Sadanandam A, Waldron L, Hussain A, Saleem M, El-Rayes B, Salahudeen A, Masood A. Refining colorectal cancer classification and clinical stratification through a single-cell atlas. Genome Biology 2022, 23: 113. PMID: 35538548, PMCID: PMC9092724, DOI: 10.1186/s13059-022-02677-z.Peer-Reviewed Original ResearchConceptsConsensus molecular subtypesTumor microenvironmentAssociated with immunotherapy resistanceCAF subtypesImmune checkpoint inhibitorsHuman CRC samplesIndependent external cohortMechanism of tumorsMSI-HContribution to pathogenesisResultsTumor cellsCheckpoint inhibitorsImmunotherapy resistanceImmunotherapy responseEpithelial levelClinicopathological characteristicsMolecular subtypesClinical stratificationCRC patientsMicroenvironmental cellsPatient prognosisPoor outcomeMSI-H CRCsBackgroundColorectal cancerColorectal cancer classification
2021
Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer
Li A, Goodyear S, Fuss C, Mitri Z. Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer. JCO Precision Oncology 2021, 5: 904-909. PMID: 34994619, DOI: 10.1200/po.20.00361.Peer-Reviewed Original Research
2018
Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer
Latham A, Srinivasan P, Kemel Y, Shia J, Bandlamudi C, Mandelker D, Middha S, Hechtman J, Zehir A, Dubard-Gault M, Tran C, Stewart C, Sheehan M, Penson A, DeLair D, Yaeger R, Vijai J, Mukherjee S, Galle J, Dickson M, Janjigian Y, O’Reilly E, Segal N, Saltz L, Reidy-Lagunes D, Varghese A, Bajorin D, Carlo M, Cadoo K, Walsh M, Weiser M, Aguilar J, Klimstra D, Diaz L, Baselga J, Zhang L, Ladanyi M, Hyman D, Solit D, Robson M, Taylor B, Offit K, Berger M, Stadler Z. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal Of Clinical Oncology 2018, 37: 286-295. PMID: 30376427, PMCID: PMC6553803, DOI: 10.1200/jco.18.00283.Peer-Reviewed Original ResearchConceptsGenetic testing criteriaPrevalence of LSFamily cancer historyMicrosatellite instabilityMSI-HMismatch repair genesMMR-D tumorsMicrosatellite instability statusHigh-frequency microsatellite instabilityPrediction of LSLynch syndromeMMR-DCancer historyCancer surveillanceEndometrial cancerPersonal/family historyUnique patientsMismatch repair deficiencyPreventive measuresCancer predispositionSolid tumorsAffected familiesTumor spectrumImmunohistochemical stainingRepair genes
2017
Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data
Middha S, Zhang L, Nafa K, Jayakumaran G, Wong D, Kim H, Sadowska J, Berger M, Delair D, Shia J, Stadler Z, Klimstra D, Ladanyi M, Zehir A, Hechtman J. Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. JCO Precision Oncology 2017, 2017: 1-17. PMID: 30211344, PMCID: PMC6130812, DOI: 10.1200/po.17.00084.Peer-Reviewed Original ResearchPolymerase chain reactionMicrosatellite instability statusColorectal cancerMicrosatellite instabilityResponse to immune checkpoint inhibitorsMSI-HImmune checkpoint inhibitorsMMR immunohistochemistryAdvanced solid cancersManagement of patientsSolid cancer typesTargeted NGS dataCheckpoint inhibitorsClinical NGS assayEndometrioid cancerMutational burdenSolid cancersNGS assayMSI polymerase chain reactionCancer typesCancerMSI-H tumorsPan-cancerNGS dataChain reaction
2009
Gene Expression Patterns in Mismatch Repair-Deficient Colorectal Cancers Highlight the Potential Therapeutic Role of Inhibitors of the Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway
Vilar E, Mukherjee B, Kuick R, Raskin L, Misek D, Taylor J, Giordano T, Hanash S, Fearon E, Rennert G, Gruber S. Gene Expression Patterns in Mismatch Repair-Deficient Colorectal Cancers Highlight the Potential Therapeutic Role of Inhibitors of the Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway. Clinical Cancer Research 2009, 15: 2829-2839. PMID: 19351759, PMCID: PMC3425357, DOI: 10.1158/1078-0432.ccr-08-2432.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsAntineoplastic AgentsBenzoquinonesCell CycleCell Line, TumorChromonesColorectal NeoplasmsComputational BiologyDNA Mismatch RepairDrug Evaluation, PreclinicalEnzyme InhibitorsGene Expression ProfilingHumansHydroxamic AcidsImmunosuppressive AgentsLactams, MacrocyclicMicrosatellite InstabilityMorpholinesPhosphoinositide-3 Kinase InhibitorsProto-Oncogene Proteins c-aktSirolimusConceptsGene expression informationColorectal cancerCell linesExpression informationGene expression dataSystems biology toolsLY-294002Gene expression patternsLow molecular weight compoundsPhosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin pathwayMutant cellsBioinformatics approachTarget of rapamycin pathwayExpression dataMismatch repair-deficient colorectal cancerMolecular weight compoundsGroup of patientsCell cycleBiology toolsApoptosis effectExpression patternsPotential therapeutic roleTrichostatin AMSI-HWeight compounds
2003
Value of Histopathology in Predicting Microsatellite Instability in Hereditary Nonpolyposis Colorectal Cancer and Sporadic Colorectal Cancer
Shia J, Ellis N, Paty P, Nash G, Qin J, Offit K, Zhang X, Markowitz A, Nafa K, Guillem J, Wong W, Gerald W, Klimstra D. Value of Histopathology in Predicting Microsatellite Instability in Hereditary Nonpolyposis Colorectal Cancer and Sporadic Colorectal Cancer. The American Journal Of Surgical Pathology 2003, 27: 1407-1417. PMID: 14576473, DOI: 10.1097/00000478-200311000-00002.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdenocarcinomaAdultAgedAged, 80 and overBiomarkers, TumorCarrier ProteinsColorectal NeoplasmsColorectal Neoplasms, Hereditary NonpolyposisDNA Mutational AnalysisDNA-Binding ProteinsDNA, NeoplasmFemaleGerm-Line MutationHumansLymphocytes, Tumor-InfiltratingMaleMicrosatellite RepeatsMiddle AgedMutL Protein Homolog 1MutS Homolog 2 ProteinNeoplasm ProteinsNuclear ProteinsPredictive Value of TestsProto-Oncogene ProteinsROC CurveSensitivity and SpecificityConceptsSporadic MSI-H tumorsHereditary nonpolyposis colorectal cancerNonpolyposis colorectal cancerMSI-H tumorsColorectal cancerFamily history of colorectal cancerHistory of colorectal cancerFamily historyHNPCC-associated cancersLevels of DNA microsatellite instabilityMSI-HDNA microsatellite instabilitySporadic colorectal cancerLogistic regression modelsAmsterdam criteriaMicrosatellite instabilityNon-MSI-H tumorsHNPCCOdds ratioPredicting MSI statusColorectal carcinomaSporadic groupTumor-infiltrating lymphocytesMSI-H colorectal carcinomasSurgical clinic
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply